Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
H2 receptor antagonist
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Tagamet
|
| gptkbp:contraindication |
liver disease
renal impairment pregnancy category B |
| gptkbp:discovered_by |
1970s
|
| gptkbp:dosage_form |
oral
intravenous |
| gptkbp:duration |
as prescribed by a doctor
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:product
gptkb:tablet injection |
| https://www.w3.org/2000/01/rdf-schema#label |
Cimetidine
|
| gptkbp:ingredients |
C10 H13 N5 S
|
| gptkbp:interacts_with |
gptkb:phenytoin
gptkb:theophylline gptkb:warfarin benzodiazepines |
| gptkbp:is_atype_of |
A02 B A01
|
| gptkbp:is_available_in |
various strengths
over-the-counter formulations prescription formulations |
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_considered |
first-line treatment for GERD
first-line treatment for peptic ulcers less effective than proton pump inhibitors |
| gptkbp:is_part_of |
H2 receptor antagonists class
|
| gptkbp:is_used_for |
treating gastroesophageal reflux disease (GERD)
preventing aspiration pneumonia preventing stomach ulcers reducing gastric acid secretion treating Zollinger-Ellison syndrome treating ulcers |
| gptkbp:is_used_in |
hospital settings
outpatient settings |
| gptkbp:lifespan |
2 hours
|
| gptkbp:marketed_as |
various pharmaceutical companies
|
| gptkbp:metabolism |
liver
|
| gptkbp:side_effect |
dizziness
headache nausea confusion diarrhea |
| gptkbp:suitable_for |
patients taking certain medications without consultation
children under 12 without medical advice elderly patients without monitoring patients with known hypersensitivity |
| gptkbp:type_of |
51481-61-9
|
| gptkbp:bfsParent |
gptkb:Sir_James_Black
|
| gptkbp:bfsLayer |
5
|